15 citations,
March 2004 in “American Journal of Ophthalmology” Using bimatoprost on one side of the face caused increased cheek hair growth in a patient.
12 citations,
November 2006 in “Journal of thoracic oncology” A cancer patient's eyelashes grew excessively without other common side effects after taking the cancer drug erlotinib.
11 citations,
November 2018 in “Journal of the American Academy of Dermatology” Tofacitinib therapy can effectively regrow eyebrows and eyelashes in some alopecia areata patients.
11 citations,
January 2012 in “PubMed” Bimatoprost can help grow eyebrow hair.
9 citations,
December 2020 in “Dermatologic Therapy” Certain drugs are effective for skin conditions like psoriasis, vitiligo, and hair loss.
9 citations,
April 2017 in “International Journal of Dermatology” Different areas of the scalp have varying hair thickness, useful for different types of hair transplant needs.
9 citations,
January 2014 in “Dermatology online journal” Bimatoprost 0.03% helps grow eyebrow hair.
7 citations,
April 2021 in “British Journal of Dermatology” Topical tofacitinib may effectively and safely regrow facial hair in some people with alopecia areata.
7 citations,
May 2018 in “Curēus” Bimatoprost 0.03% solution effectively promotes eyebrow growth.
7 citations,
July 2014 in “Facial Plastic Surgery Clinics of North America” Different ethnic hair traits must be considered for successful hair restoration surgery to achieve natural-looking results.
7 citations,
October 2006 in “Medical hypotheses” UV light might cause excessive hair growth by increasing PGE2 in the skin.
6 citations,
February 2023 in “Journal of the American Academy of Dermatology” Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
6 citations,
July 2017 in “Clinics in Plastic Surgery” The document concludes that individualized reconstruction plans are essential for improving function and appearance after head and neck burns.
6 citations,
January 2017 in “British Journal of Dermatology” Frontal fibrosing alopecia is a scarring hair loss condition mainly affecting older women, with no known cause and treatments that may help stabilize hair loss.
6 citations,
July 2008 in “Clinical and experimental optometry” Prostaglandin eye drops for glaucoma can rarely cause too much cheek hair growth.
5 citations,
July 2010 in “Archives of Internal Medicine” Prostaglandins may protect hair follicles during chemotherapy.
5 citations,
March 2014 in “Journal of The American Academy of Dermatology” The study suggests hormonal factors may play a role in Frontal Fibrosing Alopecia and that treatments like oral antiandrogens and steroids could be beneficial.
3 citations,
September 2022 in “Journal of the American Academy of Dermatology” Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
3 citations,
October 2020 in “Journal of Investigative Dermatology Symposium Proceedings” The main goal for new Alopecia Areata treatments should be significant improvement in scalp hair growth.
3 citations,
May 2019 in “Journal of Cosmetic Dermatology” Miliacin with polar lipids helps hair growth and improves hair loss in women.
2 citations,
March 1996 in “Journal of The American Academy of Dermatology” The book is an updated guide on hair transplant techniques, useful for beginners and professionals.
1 citations,
August 2018 in “Journal of the American Academy of Dermatology” A young woman developed facial bumps before hair loss, which is unusual for her condition.
1 citations,
January 2015 in “International Journal of Pediatrics and Adolescent Medicine” Cyclosporine-A can cause excessive hair growth, which usually stops after discontinuing the drug.
1 citations,
January 2013 Bimatoprost treats glaucoma and promotes hair growth, with potential for more medical uses.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
September 2024 in “Journal of the American Academy of Dermatology” Facebook groups play a crucial role in supporting and guiding patients on scalp cooling and hair loss during chemotherapy.
August 2024 in “Journal of the American Academy of Dermatology” Baricitinib effectively promotes hair regrowth in both scalp and nonscalp areas for alopecia areata universalis patients.
June 2023 in “British Journal of Dermatology” Baricitinib was effective and safe for severe hair loss treatment over 6 months.
The document concludes that the girl's hairlessness is likely inherited from her parents.
September 2022 in “Journal of Investigative Dermatology” Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.